The end of a shortage of popular weight-loss drugs may mean many people lose access to them [Video]

If there’s a diet, Janet McCaskill says, she’s done it.”I’ve tried WeightWatchers. I’ve tried keto. I’ve gone to a nutritionist,” said the 58-year-old grandmother, who lives in Knightdale, North Carolina, outside Raleigh. Some of the eating plans worked, she said – until they didn’t.Related video above: WeightWatchers offers version of Ozempic, despite FDA concernsAt the end of 2022, weighing about 212 pounds and fearful about her health after losing her brother and both parents to heart disease, McCaskill started using the diabetes drug Mounjaro off-label for weight loss. It’s part of a class of drugs known as GLP-1 receptor agonists, which also includes Ozempic, Wegovy and Zepbound.”It literally saved my life,” she said.But it was expensive, and after switching to a lower-cost version made by a compounding pharmacy last year, McCaskill now is worried she’ll lose access to her medication because the U.S. Food and Drug Administration determined that a …